

Product Pipeline

	Phase I	Phase II	Phase III	Registration	Approval
<u>Neratinib: Tyrosine kinase inhibitor</u>					
HER2+ Breast Cancer	ExteNET (Phase III HER2+ EBC*)				
Extended adjuvant <i>Neratinib monotherapy</i>	CONTROL				
Metastatic <i>Monotherapy or combo therapy</i>	NALA (Phase III 3rd Line HER2+ MBC**)				
Metastatic HER2 amplified/mutated <i>Combo with trastuzumab deruxtecan</i>	NCT05372614				
<u>Alisertib: Aurora kinase A inhibitor</u>					
HRc+*** HER2-negative MBC	TBCRC-041 (fulvestrant + alisertib)				
	ALISCA™-Breast 1 (alisertib+endocrine)				
Metastatic EGFR-mutant NSCLC****	NCT04085315 (alisertib+osimertinib)				
Small cell lung cancer	ALISCA™-Lung1 (PUMA-ALI-4201)				

*

*